WeVote
Log In

Bill

Bill

HB 466

AN ACT TO AMEND TITLE 16 OF THE DELAWARE CODE RELATING TO THE APPLICATION OF NASAL EPINEPHRINE.

153rd General Assembly (2025-2026) Introduced by DeShanna Neal and 2 co-sponsors

HB 466 creates a framework to stock, train for, and administer nasal epinephrine in authorized settings to improve timely emergency response.

Passed By Senate. Votes: 21 YES
0
WeVote Research Nonpartisan
Bill Summary · HB 466

Overview

HB 466 (Session 153, Delaware) seeks to amend Title 16 of the Delaware Code concerning the application of nasal epinephrine. The bill was introduced on June 4, 2026, and assigned to the Health & Human Development Committee in the House. Primary sponsors include Dave Sokola and DeShanna Neal (co-sponsors).

Purpose and intent

  • Establishes statutory framework related to the administration, availability, or use of nasal epinephrine (a form of epinephrine delivered via nasal spray) in specified settings.
  • Aims to clarify responsibilities and procedures to improve accessibility and timely use of nasal epinephrine for individuals experiencing severe allergic reactions or other indicated medical situations.
  • Addresses how nasal epinephrine should be stored, accessed, and administered in authorized environments, with the goal of enhancing emergency response and reducing barriers to use.

Key provisions and changes (as typically included in such amendments)

Note: The exact text of HB 466 is not provided here, but expected provisions based on the bill’s scope likely include:
- Definitions: Clarification of terms related to nasal epinephrine, including who is authorized to administer and in what settings (e.g., schools, child care facilities, workplaces, healthcare facilities).
- Access and Availability: Provisions to ensure nasal epinephrine products are readily available in trained settings, with procedures for stocking, inventory management, and accountability.
- Administration and Training: Requirements for individuals who may administer nasal epinephrine (e.g., staff in schools or camps) to receive appropriate training, recognition of emergency situations, and steps for administration.
- Liability and Good Samaritan Protections: Provisions to protect administrators and facilities from liability when acting in good faith to administer nasal epinephrine in an emergency, with specified conditions.
- Notification and Reporting: Requirements to notify parents/guardians, medical professionals, and appropriate authorities after administration, and possibly reporting to state health departments or school systems.
- Storage and Expiration: Guidelines on storage conditions, stock rotation, and disposal of expired devices.
- Funding and Implementation: Potential references to funding mechanisms, oversight, and effective dates for implementation in agencies or institutions.

Who would be affected

  • Individuals at risk of severe allergic reactions who rely on timely epinephrine administration.
  • Institutions where nasal epinephrine would be stocked for emergencies (e.g., schools, childcare facilities, camps, workplaces, health care settings).
  • Staff and volunteers in these institutions who may be trained to administer nasal epinephrine.
  • School districts, child welfare agencies, and related departments responsible for policy and compliance.
  • Medical professionals and parents/guardians who must be notified or involved in post-administration care.

Procedural and timeline aspects

  • Introduction date: June 4, 2026.
  • Assigned to the House Health & Human Development Committee for consideration and potential hearings.
  • If advanced, HB 466 would proceed through committee markup, potential amendments, and floor votes in the Delaware House, then to the Senate for a parallel process (subject to Delaware legislative rules and timelines).
  • Final enactment would require passage by both chambers and approval by the governor, followed by any effective dates specified in the bill.

Practical considerations and impact

  • Potential improvement in response times during anaphylactic events or other indicated conditions, particularly in settings with ready access to nasal epinephrine.
  • Clarification of liability and training expectations could encourage broader adoption and reduce hesitation among staff.
  • Implementation costs related to stocking, training, and ongoing management of nasal epinephrine supplies.
  • The bill’s effectiveness will depend on accompanying regulations, funding, and compliance measures enacted during the legislative process.

If you’d like, I can refine this summary once the final text or additional committee analyses become available, and I can highlight exact sections and statutory changes verbatim.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.